<DOC>
	<DOCNO>NCT00014079</DOCNO>
	<brief_summary>RATIONALE : Determination genetic marker colorectal cancer may improve identification patient high risk relapse . PURPOSE : This clinical trial study importance genetic marker detect relapse patient colorectal cancer .</brief_summary>
	<brief_title>Genetic Markers Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical pathologic significance unstable DNA element colorectal cancer ( tumor microsatellite instability ) . - Determine clinical pathologic significance loss heterozygosity chromosomes 5 , 8 , 17 , 18 ( primary target ) chromosomes 1 , 14 , 22 ( secondary target ) colorectal cancer . OUTLINE : DNA examine unstable element ( microsatellite instability loss heterozygosity ) analyze least 10 separate ( CA ) n-repeats localize 5 separate chromosome ( 5q , 8p , 15 , 17p , 18q ) . Loss heterozygosity analyze least four chromosomal arm ( 5q , 8p , 17p , 18q ) later chromosome ( e.g. , 1 , 14 , 22 ) . Immunohistochemistry use test presence absence gene involve DNA mismatch repair ( hMLH1 hMSH2 ) . Patients receive result genetic test result influence type duration treatment . PROJECTED ACCRUAL : This study accrue 708 specimen .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must resectable adenocarcinoma colon rectum must participate one follow NCCTG randomize clinical trial : 784852 : No Treatment Control Versus Levamisole Versus Levamisole Plus Fluorouracil ( 5FU ) 794604 : No Treatment Control Versus 5FU Portal Vein Infusion 794751 : Postoperative Radiation Versus Postoperative Radiation Plus Sequential Chemotherapy Methyl CCNU 5FU 844652 : An Intergroup Study An Evaluation Levamisole Plus 5FU Surgical Adjuvant Treatment Resectable Adenocarcinoma Colon 864751 : Phase III Protocol Surgical Adjuvant Therapy Rectal Carcinoma : A Controller Evaluation ( A ) ProtractedInfusion 5FU Radiation Enhancer ( B ) 5FU Plus MethylCCNU Chemotherapy 874651 : M/N A Controller Evaluation Recombinant Interferongamma ( IFL GM ) 5FU Folinic Acid With Without Levamisole Adjuvant Treatment Resectable Adenocarcinoma Colon 894651 : A Controller Phase III Evaluation 5FU Combined With Levamisole Leucovorin Adjuvant Treatment Resectable Colon Cancer Tissue block primary colorectal cancer must receive NCCTG operation office</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>